Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) Director Sells $547,800.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Mahesh Krishnan sold 7,304 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares in the company, valued at approximately $1,084,650. The trade was a 33.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Halozyme Therapeutics Stock Up 3.2%

NASDAQ HALO opened at $79.45 on Friday. The stock has a 50 day moving average price of $69.18 and a 200-day moving average price of $69.35. Halozyme Therapeutics, Inc. has a one year low of $53.33 and a one year high of $82.22. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The company has a market capitalization of $9.42 billion, a P/E ratio of 28.58, a P/E/G ratio of 0.32 and a beta of 0.84.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. Halozyme Therapeutics’s quarterly revenue was up 42.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Empowered Funds LLC purchased a new position in shares of Halozyme Therapeutics during the first quarter valued at approximately $755,000. Acadian Asset Management LLC purchased a new stake in shares of Halozyme Therapeutics in the first quarter worth approximately $195,000. Hsbc Holdings PLC lifted its stake in shares of Halozyme Therapeutics by 117.1% during the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after acquiring an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 174 shares during the last quarter. Finally, Baird Financial Group Inc. boosted its holdings in Halozyme Therapeutics by 6.2% during the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 650 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, May 16th. UBS Group reissued a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. Eight equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.60.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.